The emergence of cancer drug resistance remains one of the most pressing problems in cancer care and there is a critical need to devise approaches to mitigate it. However, the molecular mechanisms driving treatment resistance are poorly understood, hindering efforts to devise new treatment strategies which prevent resistance.
This article was originally published on MedicalXpress.com

